Elinzanetant reduced vasomotor symptoms frequency and severity in women with or at high risk of HR-positive breast cancer in ...

Panelists discuss the findings from the DESTINY-Breast12 study, focusing on the efficacy and safety of trastuzumab deruxtecan in patients with HER2-low breast cancer and its potential to expand ...

Here are the most anticipated abstracts to keep an eye on going into the 2025 ASCO Gastrointestinal Cancers Symposium.

Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving ...

The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the ...